Filing Flows

Filing Flows › Companies › Allogene Therapeutics › Cash flow

Allogene Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$36.1M in Q3 2026 · −$109M over twelve months

Operating cash flow−$36.1M
Capital spending−$25K
Free cash flow−$36.1M

Analysis

In Q3 2026, Allogene Therapeutics generated −$36.1M of operating cash flow and spent $25K on capital projects, leaving free cash flow of −$36.1M. That is $6.2M less than in Q3 2025 (−$29.9M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$109M; the largest uses were other investing ($117M), operating cash flow ($109M), capital spending ($184K); besides operations, cash came from other financing ($217M), shares issued ($4K); the cash balance fell by $8.5M.

Operating cash flow was −$36.1M against net income of −$50.4M. The largest differences: stock-based pay +$7.0M, accrued liabilities +$3.7M, payables +$2.8M.

Free cash flow

Allogene Therapeutics: free cash flow by quarterAllogene Therapeutics: free cash flow by quarter−$37.0MQ4 2024−$53.0MQ1 2025−$39.1MQ2 2025−$29.9MQ3 2025−$27.6MQ4 2025−$12.9MQ1 2026−$32.1MQ2 2026−$36.1MQ3 2026
Operating cash flow less capital spending.
Allogene Therapeutics: operating cash flow against capital spendingAllogene Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$36.7M$257KQ4 2024−$52.9M$99KQ1 2025−$39.0M$44KQ2 2025−$29.7M$243KQ3 2025−$27.6M$0Q4 2025−$12.9M$9KQ1 2026−$32.0M$150KQ2 2026−$36.1M$25KQ3 2026
Latest (Q3 2026): Operating cash flow −$36.1M, Capital spending $25K.

Capital allocation, year by year

Allogene Therapeutics: where the cash came from (up) and went (down), by fiscal yearAllogene Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$185MFY2021: Shares issued $8.3MFY2021: Capital spending −$21.4M$8.3MFY2021FY2022: Operating cash flow −$221MFY2022: Shares issued $489KFY2022: Capital spending −$5.2M$489KFY2022FY2023: Operating cash flow −$238MFY2023: Shares issued $93.2MFY2023: Capital spending −$1.5M$93.2MFY2023FY2024: Operating cash flow −$200MFY2024: Shares issued $813KFY2024: Capital spending −$694K$813KFY2024FY2025: Operating cash flow −$149MFY2025: Capital spending −$386KFY2025
Over these 5 years operating cash flow totalled −$993M; the largest uses were operating cash flow ($993M) and capital spending ($29.2M). Cash-flow statements as filed.

Where the cash came from and went

Allogene Therapeutics: sources (+) and uses (−) of cash, Q3 2026Allogene Therapeutics: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$36.1MOther investing$26.1MCash drawn (+) / kept (−)$9.4MOther financing$646KCapital spending−$25K
Allogene Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Allogene Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$217MOther investing−$117MOperating cash flow−$109MCash drawn (+) / kept (−)$8.5MCapital spending−$184KShares issued$4K

From profit to cash

Allogene Therapeutics: net income to operating cash flow, Q3 2026Allogene Therapeutics: net income to operating cash flow, Q3 2026Net income−$50.4MDepreciation & amortization$2.6MStock-based pay$7.0MPayables$2.8MAccrued liabilities$3.7MPrepaid and other assets$528KOperating cash flow−$36.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$36.1M−$25K—$9.4M−$36.1M
Q2 2026−$32.0M−$150K—−$8.3M−$32.1M
Q1 2026−$12.9M−$9K$4K$21.4M−$12.9M
Q4 2025−$27.6M——−$13.9M−$27.6M
Q3 2025−$29.7M−$243K—$14.5M−$29.9M
Q2 2025−$39.0M−$44K—−$9.9M−$39.1M
Q1 2025−$52.9M−$99K$10.0M$32.8M−$53.0M
Q4 2024−$36.7M−$257K—−$24.0M−$37.0M

Allogene Therapeutics: income statement and cash flow

Allogene Therapeutics, Q2 2026: revenue $4.6M. The chart follows the revenue to costs, profit and cash.

Allogene Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.